Head-to-head · WeighScore
HealthRX vs Intimate Rose
The verdict
HealthRX takes it — 86.1/100 to 65.1/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HealthRX | Intimate Rose |
|---|---|---|
| WeighScore | 86.1/100 | 65.1/100 |
| Grade | B | C |
| Scorecard rank | #6 | #247 |
| Semaglutide | $190/mo month-to-month ($99 first month, renews at $165) · $99/mo on a 12-month prepay ($1,188) | $169/mo (all doses, compounded) |
| Tirzepatide | $239/mo month-to-month ($149 first month, renews at $214) · $179/mo on a 12-month prepay ($2,148) | $169/mo (all doses, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #6 · B
Strengths
- Physician-supervised intake with licensed providers
- Both molecules plus a rare oral GLP tablet option
- Transparent flat monthly pricing, no insurance required
Where it loses points
- Compounded semaglutide/tirzepatide is not FDA-approved
- Some tiers are company-stated and the public site is thin
- Brand Ozempic is a steep pass-through (~$1,299)
- State count is not publicly listed
Graded #247 · C
FDAWarning letter issued to Intimate Rose in September 2025. See the FDA warning-letter database.
Strengths
- Transparent pricing from 169 dollars per month shown upfront, not gated behind intake
- Medication and free delivery included, HSA and FSA eligible, no contract
- Backed by an established women's-health brand using the OpenLoop provider network
Where it loses points
- State availability not published
- Oral compounded GLP-1 only; no injectable option shown
- No specific compounding pharmacy named (network fulfillment via OpenLoop)
- FDA issued Intimate Rose a warning letter in September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.